NASDAQ:CRBP Corbus Pharmaceuticals Q2 2026 Earnings Report $6.92 -0.22 (-3.08%) Closing price 04:00 PM EasternExtended Trading$7.05 +0.13 (+1.86%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Corbus Pharmaceuticals EPS ResultsActual EPS-$1.81Consensus EPS -$1.26Beat/MissMissed by -$0.55One Year Ago EPSN/ACorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACorbus Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsCorbus Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Corbus Pharmaceuticals Earnings HeadlinesWedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)September 17, 2026 | theglobeandmail.comCorbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy TranscriptSeptember 14, 2026 | seekingalpha.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 28 at 1:00 AM | Stansberry Research (Ad)Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial DataSeptember 14, 2026 | finance.yahoo.comCorbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'September 14, 2026 | benzinga.comCorbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock UpSeptember 14, 2026 | rttnews.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis. Corbus’s oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease. These programs are being evaluated as potential treatments for patients with difficult-to-treat cancers. The company was founded in 2009 and initially focused on therapies for inflammatory and fibrotic diseases, including systemic sclerosis and cystic fibrosis. Corbus later shifted its strategic emphasis toward oncology and expanded its pipeline through internal research and licensing activities. Its operations and clinical development activities are centered in the United States, with research and development programs intended to serve international patient populations. Yuval Cohen, Ph.D., serves as Corbus Pharmaceuticals’ chief executive officer and has led the company through its transition from an inflammation-focused biotechnology company to an oncology-focused developer.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
